Relationship between the circulating N-terminal pro B-type natriuretic peptide and the risk of carotid artery plaque in different glucose metabolic states in patients with coronary heart disease: a CSCD-TCM (plus) study in China

What Was Tested

The paper reports a study of BNP (Nesiritide), published as a clinical trial.

Studies on the association and diagnostic value of NT-proBNP in carotid plaques (CAP) in patients with CHD are limited.

Logistic regression analyses were used to compare the relationship between NT-proBNP and the risk of CAP occurrence and the number and nature of CAP.

Who Took Part

According to the abstract, 5,093 patients were involved.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

The relationships between NT-proBNP and the risk of CAP in different glucose metabolic states, sexes, and age categories were also examined using 5,093 patients diagnosed with CHD.

The NT-proBNP tertiles were used to divide patients into three groups in which the NT-proBNP levels, blood glucose levels, the occurrence of CAP, and the number and nature of CAP were measured using normoglycemic (NG), prediabetes (Pre-DM), and diabetes mellitus (DM) glucose metabolic statuses.

How the Study Was Run

The diagnostic value of NT-proBNP for CAP risk was measured using receiver operating characteristic (ROC) curves.

What Was Measured

PubMed files the paper under topics including Biomarkers, Carotid Stenosis, Coronary Disease, Glucose, Natriuretic Peptide, Brain, Peptide Fragments and Plaque, Atherosclerotic.

Author keywords: Carotid artery plaque, Circulating N-terminal pro B-type natriuretic peptide, Coronary heart disease and Glucose metabolic states.

What This Means in Plain Language

This is a clinical trial of BNP (Nesiritide) in 5,093 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Cardiovascular diabetology), a journal based in England.

More context: the BNP (Nesiritide) compound page, all human trials.